0001193125-24-093194.txt : 20240411 0001193125-24-093194.hdr.sgml : 20240411 20240411160538 ACCESSION NUMBER: 0001193125-24-093194 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 24838538 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-K/A 1 d807955d10ka.htm 10-K/A 10-K/A
true0000310158FY 0000310158 2023-01-01 2023-12-31 0000310158 2023-06-30 0000310158 2024-01-31 0000310158 mrk:A2.500NotesDue2034Member 2023-01-01 2023-12-31 0000310158 mrk:A1.375NotesDue2036Member 2023-01-01 2023-12-31 0000310158 mrk:A0.500NotesDue2024Member 2023-01-01 2023-12-31 0000310158 mrk:A1.875NotesDue2026Member 2023-01-01 2023-12-31 iso4217:USD xbrli:shares
As filed with the Securities and Exchange Commission on April 11, 2024
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
 
 
FORM 10-K/A
(Amendment No. 1)
 
 
 
☒
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023
OR
 
☐
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from
     
to
     
Commission File No. 1-6571
 
 
 
LOGO
Merck & Co., Inc.
 
 
126 East Lincoln Avenue
Rahway New Jersey 07065
(908) 740-4000
 
New Jersey
  
22-1918501
(State or other jurisdiction
of incorporation)
  
(I.R.S. Employer
Identification No.)
Securities Registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
  
Trading
Symbol(s)
  
Name of Each Exchange
on which Registered
Common Stock ($0.50 par value)
  
MRK
  
New York Stock Exchange
0.500% Notes due 2024
  
MRK 24
  
New York Stock Exchange
1.875% Notes due 2026
  
MRK/26
  
New York Stock Exchange
2.500% Notes due 2034
  
MRK/34
  
New York Stock Exchange
1.375% Notes due 2036
  
MRK 36A
  
New York Stock Exchange
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 
Yes
 ☒ 
No 
☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
 
Yes
 ☐ 
No 
☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 
Yes 
☒ 
No 
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 
Yes 
☒ 
No 
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer   ☒    Accelerated filer   ☐
Non-accelerated filer
   ☐    Smaller reporting company   ☐
     Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act). 
Yes 
☐
 No 
☒
Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2024: 2,532,643,872.
Aggregate market value of Common Stock ($0.50 par value) held by
non-affiliates
on June 30, 2023 based on the closing price on June 30, 2023: $292,929,000,000.
Documents Incorporated by Reference:
 
Document
   
Part of Form 10-K
Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024, to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report
    Part III
 
 
 
EXPLANATORY NOTE
Merck & Co., Inc. (the “Company”) filed its Annual Report on Form
10-K
for the fiscal year ended December 31, 2023 (the “Original Form
10-K”)
with the Securities and Exchange Commission on February 26, 2024. The Company is filing this Amendment No. 1 (this “Amendment”) to the Original Form
10-K
solely to correct the date of the Annual Meeting of Shareholders. In the Original Form
10-K,
that date was inadvertently referenced as May 18, 2024. The date of the Annual Meeting of Shareholders is May 28, 2024.
Accordingly, this Amendment is being filed solely to:
 
  •  
amend Part III, Items 10, 11, 12, 13 and 14 of the Original Form
10-K
to correct the date of the Annual Meeting of Shareholders;
 
  •  
correct the date of the Annual Meeting of Shareholders on the cover of the filing; and
 
  •  
file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment under Item 15 of Part IV hereof pursuant to Rule
12b-15
under the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
This Amendment does not reflect any events occurring after the filing of the Original Form
10-K
or modify or update the disclosure contained therein in any way other than as required to reflect the correction discussed above. Accordingly, this Amendment should be read in conjunction with the Original Form
10-K.

Table of Contents

 

         Page  
  Part III   
Item 10.  

Directors, Executive Officers and Corporate Governance

      1  
Item 11.  

Executive Compensation

      1  
Item 12.  

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

      2  
Item 13.  

Certain Relationships and Related Transactions, and Director Independence

      2  
Item 14.  

Principal Accountant Fees and Services

      2  
  Part IV   
Item 15.  

Exhibits and Financial Statement Schedules

      3  
 

Signatures

      9  

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance.

The required information on directors and nominees is incorporated by reference from the discussion under Proposal 1. Election of Directors of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024. Information on executive officers is set forth in Part I of the Original Form 10-K on page 41.

The required information on compliance with Section 16(a) of the Securities Exchange Act of 1934, if applicable, is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

The Company has a Code of Conduct — Our Values and Standards applicable to all employees, including the principal executive officer, principal financial officer, principal accounting officer and Controller. The Code of Conduct is available on the Company’s website at www.merck.com/company-overview/culture-and-values/code-of- conduct/values-and-standards/. The Company intends to disclose future amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers and directors, if any, on the website within four business days following the date of any amendment or waiver. Every Merck employee is responsible for adhering to business practices that are in accordance with the law and with ethical principles that reflect the highest standards of corporate and individual behavior.

The required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading “Board Meetings and Committees” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

 

Item 11.

Executive Compensation.

The information required on executive compensation is incorporated by reference from the discussion under the headings “Compensation Discussion and Analysis,” “Summary Compensation Table,” “All Other Compensation” table, “CEO Pay Ratio,” “Pay vs. Performance” table, “Grants of Plan-Based Awards” table, “Outstanding Equity Awards” table, “Option Exercises and Stock Vested” table, “Pension Benefits” table, “Nonqualified Deferred Compensation” table, and “Potential Payments Upon Termination or a Change in Control”, including the discussion under the subheadings “Separation” and “Change in Control,” as well as all footnote information to the various tables, of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

The required information on director compensation is incorporated by reference from the discussion under the heading “Director Compensation” and related “2023 Schedule of Director Fees” table and “2023 Director Compensation” table of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

The required information under the headings “Compensation and Management Development Committee Interlocks and Insider Participation” and “Compensation and Management Development Committee Report” is incorporated by reference from the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

 

1

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

Equity Compensation Plan Information

The following table summarizes information about the options, warrants and rights and other equity compensation under the Company’s equity compensation plans as of the close of business on December 31, 2023. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.

 

Plan Category    Number of securities to be
issued upon exercise of
outstanding options,
warrants and rights
(a)		     Weighted-average exercise
price of outstanding
options, warrants and
rights
(b)		      Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
(c)		  

Equity compensation plans approved by security holders(1)

      13,526,932 (2)    $ 77.54        81,123,362  

Equity compensation plans not approved by security holders

      —        —         —   
  

 

 

    

 

 

     

 

 

  

Total

      13,526,932     $ 77.54        81,123,362  

 

(1)

Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck & Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck & Co., Inc. 2010 Non-Employee Directors Stock Option Plan.

(2)

Excludes approximately 12,541,646 shares of restricted stock units and 1,966,333 performance share units (assuming maximum payouts) under the Merck Sharp & Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 157,619 shares of phantom stock deferred under the MSD Employee Deferral Program and 503,549 shares of phantom stock deferred under the Merck & Co., Inc. Plan for Deferred Payment of Directors’ Compensation.

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

The required information on transactions with related persons is incorporated by reference from the discussion under the heading “Related Person Transactions” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

The required information on director independence is incorporated by reference from the discussion under the heading “Independence of Directors” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

 

Item 14.

Principal Accountant Fees and Services.

The information required for this item is incorporated by reference from the discussion under Proposal 4. Ratification of Appointment of Independent Registered Public Accounting Firm for 2024 beginning with the caption “Pre-Approval Policy for Services of Independent Registered Public Accounting Firm” through “Fees for Services Provided by the Independent Registered Public Accounting Firm” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024.

 

2

PART IV

 

Item 15.

Exhibits and Financial Statement Schedules.

 

  (a)

The following documents are filed as part of this Form 10-K/A

 

  3.

Exhibits

 

Exhibit
Number

        

Description

  1.1    —    Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) — Incorporated by reference to Merck & Co., Inc.’s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)
  1.2    —    By-Laws of Merck & Co., Inc. (effective March 22, 2022) — Incorporated by reference to Merck & Co., Inc.’s Current Report on Form 8-K filed March 25, 2022 (No. 1-6571)
  4.1    —    Indenture, dated as of April 1, 1991, between Merck Sharp & Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New York), as Trustee (the 1991 Indenture) — Incorporated by reference to Exhibit 4 to MSD’s Registration Statement on Form S-3 (No. 33-39349)
  4.2    —    First Supplemental Indenture to the 1991 Indenture, dated as of October 1, 1997 — Incorporated by reference to Exhibit 4(b) to MSD’s Registration Statement on Form S-3 filed September 25, 1997 (No. 333-36383)
  4.3    —    Second Supplemental Indenture to the 1991 Indenture, dated November 3, 2009 — Incorporated by reference to Exhibit 4.3 to Merck & Co., Inc.’s Current Report on Form 8-K filed November 4, 2009 (No.1-6571)
  4.4    —    Third Supplemental Indenture to the 1991 Indenture, dated May 1, 2012 — Incorporated by reference to Exhibit 4.1 to Merck & Co., Inc.’s Form 10-Q Quarterly Report for the period ended March 31, 2012 (No. 1-6571)
  4.5    —    Indenture, dated November 26, 2003, between Merck & Co., Inc. (f/k/a Schering-Plough Corporation) and The Bank of New York as Trustee (the 2003 Indenture) — Incorporated by reference to Exhibit 4.1 to Schering-Plough’s Current Report on Form 8-K filed November 28, 2003 (No. 1-6571)
  4.6    —    Second Supplemental Indenture to the 2003 Indenture (including Form of Note), dated November 26, 2003 — Incorporated by reference to Exhibit 4.3 to Schering-Plough’s Current Report on Form 8-K filed November 28, 2003 (No. 1-6571)
  4.7    —    Third Supplemental Indenture to the 2003 Indenture (including Form of Note), dated September 17, 2007 — Incorporated by reference to Exhibit 4.1 to Schering-Plough’s Current Report on Form 8-K filed September 17, 2007 (No. 1-6571)
  4.8    —    Fifth Supplemental Indenture to the 2003 Indenture, dated November 3, 2009 — Incorporated by reference to Exhibit 4.4 to Merck & Co., Inc.’s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)

 

3

  4.9    —    Indenture, dated as of January 6, 2010, between Merck & Co., Inc. and U.S. Bank Trust National Association, as Trustee — Incorporated by reference to Exhibit 4.1 to Merck & Co., Inc.’s Current Report on Form 8-K filed December 10, 2010 (No. 1-6571)
  4.10    —    Description of the Registrant’s Common Stock—Incorporated by reference to Exhibit 4.10 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)
  4.11    —    Description of the Registrant’s 1.125% Notes due 2021, 1.875% Notes due 2026, and 2.500% Notes due 2034—Incorporated by reference to Exhibit 4.11 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)
  4.12    —    Description of the Registrant’s 0.500% Notes due 2024 and 1.375% Notes due 2036—Incorporated by reference to Exhibit 4.12 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)
*10.1    —    Merck & Co., Inc. Executive Incentive Plan (as amended and restated effective June 1, 2015) — Incorporated by reference to Merck & Co., Inc.’s Schedule 14A filed April 13, 2015 (No. 1-6571)
*10.2    —    Merck & Co., Inc. Deferral Program Including the Base Salary Deferral Plan (Amended and Restated effective December 1, 2019)—Incorporated by reference to Exhibit 10.2 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2019 filed February 26, 2020 (No. 1-6571)
*10.3    —    Merck & Co., Inc. 2010 Incentive Stock Plan (as amended and restated June 1, 2015) — Incorporated by reference to Merck & Co., Inc.’s Schedule 14A filed April 13, 2015 (No. 1-6571)
*10.4    —    Form of stock option terms for 2013 quarterly and annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan — Incorporated by reference to Exhibit 10.19 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2012 filed February 28, 2013 (No. 1-6571)
*10.5    —    Form of stock option terms for 2014 quarterly and annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan — Incorporated by reference to Exhibit 10.18 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2014 filed February 27, 2015 (No. 1-6571)
*10.6    —    Form of stock option terms for 2015 quarterly and annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan — Incorporated by reference to Exhibit 10.20 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2015 filed February 26, 2016 (No. 1-6571)
*10.7    —    Form of stock option terms for 2017 annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan—Incorporated by reference to Exhibit 10.7 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)

 

4

*10.8    —    Form of stock option terms for 2019 annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan—Incorporated by reference to Exhibit 10.8 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.9    —    Form of stock option terms for 2018 quarterly and annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan — Incorporated by reference to Exhibit 10.12 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2017 filed February 27, 2018 (No. 1-6571)
*10.10    —    Form of stock option terms for 2016 quarterly and annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan — Incorporated by reference to Exhibit 10.19 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2016 filed February 28, 2017 (No. 1-6571)
*10.11    —    Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Appendix C to Merck & Co., Inc.’s Schedule 14A filed April 8, 2019 (No. 1-6571) and to the Registration Statement on Form S-8 filed August 12, 2019 to register 111,000,000 shares under the 2019 Incentive Stock Plan (File No. 333-233226)
*10.12    —    Merck & Co., Inc. Change in Control Separation Benefits Plan (effective as amended and restated, as of January 1, 2013) — Incorporated by reference to Exhibit 10.1 to Merck & Co., Inc.’s Current Report on Form 8-K filed November 29, 2012 (No. 1-6571)
*10.13    —    Merck & Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) as further amended by Amendments 2019-1 (as of December 19, 2019), 2020-1 (as of February 25, 2020), 2020-2 (as of December 10, 2020), 2021-1 (as of March 31, 2021), 2021-2 (as of December 16, 2021), 2022-1 (as of December 14, 2022) and 2022-2 (as of December 13, 2021)—Incorporated by reference to Exhibit 10.13 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.14    —    Retirement Plan for the Directors of Merck & Co., Inc. (amended and restated June 21, 1996) — Incorporated by reference to Exhibit 10.C to MSD’s Form 10-Q Quarterly Report for the period ended June 30, 1996 filed August 13, 1996 (No. 1-3305)
*10.15    —    Merck & Co., Inc. Plan for Deferred Payment of Directors’ Compensation (Amended and Restated effective as of January 1, 2022)—Incorporated by reference to Exhibit 10.17 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2021 filed February 25, 2022 (No. 1-6571)
*10.16    —    Offer Letter between Merck & Co., Inc. and Jennifer Zachary, dated March 16, 2018—Incorporated by reference to Exhibit 10.28 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)

 

5

*10.17    —    Form of stock option terms for 2021 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.23 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)
*10.18    —    Form of restricted stock unit terms for 2021 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.24 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)
*10.19    —    Form of stock option terms for 2022 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.24 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2021 filed February 25, 2022 (No. 1-6571)
*10.20    —    Form of restricted stock unit terms for 2022 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.25 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2021 filed February 25, 2022 (No. 1-6571)
*10.21    —    Form of stock option terms for 2020 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.21 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.22    —    Form of restricted stock unit terms for 2020 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.22 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.23    —    2021 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.23 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.24    —    Terms for Restricted Stock Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.24 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.25    —    Restricted stock unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.25 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.26    —    Performance share unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck & Co., Inc. 2019 Incentive Stock Plan—Incorporated by reference to Exhibit 10.26 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
*10.27    —    Form of stock option terms for 2023 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.27 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)

 

6

*10.28    —    2022 Performance Share Unit terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.28 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
*10.29    —    2023 Performance Share Unit terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.29 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
*10.30    —    Offer Letter between Merck & Co., Inc. and Chirfi Guindo, dated June 8, 2022—Incorporated by reference to Exhibit 10.30 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571)
 21    —    Subsidiaries of Merck & Co., Inc. — Incorporated by reference to Exhibit 21 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 23    —    Consent of Independent Registered Public Accounting Firm — Incorporated by reference to Exhibit 23 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 24.1    —    Power of Attorney — Incorporated by reference to Exhibit 24.1 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 24.2    —    Certified Resolution of Board of Directors — Incorporated by reference to Exhibit 24.2 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 31.1    —    Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer — Incorporated by reference to Exhibit 31.1 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 31.2    —    Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer — Incorporated by reference to Exhibit 31.2 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 31.3    —    Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
 31.4    —    Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
 32.1    —    Section 1350 Certification of Chief Executive Officer — Incorporated by reference to Exhibit 32.1 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 32.2    —    Section 1350 Certification of Chief Financial Officer — Incorporated by reference to Exhibit 32.2 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)
 97    —    Policy and Procedures for Recoupment of Incentive-Based Compensation — Incorporated by reference to Exhibit 10.28 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571)

 

7

Exhibit 101:      
101.INS    —    XBRL Instance Document—The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH    —    XBRL Taxonomy Extension Schema Document.
101.CAL    —    XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF    —    XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB    —    XBRL Taxonomy Extension Label Linkbase Document.
101.PRE    —    XBRL Taxonomy Extension Presentation Linkbase Document.
104    —    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*

Management contract or compensatory plan or arrangement.

†

Certain portions of the exhibit have been omitted pursuant to a request for confidential treatment. The non-public information has been filed separately with the Securities and Exchange Commission pursuant to rule 24b-2 under the Securities Exchange Act of 1934, as amended.

Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of Merck & Co., Inc.’s total consolidated assets are not filed as exhibits to this report. Merck & Co., Inc. will furnish a copy of these agreements to the Securities and Exchange Commission on request.

 

8

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 11, 2024

 

MERCK & CO., INC.
By:   ROBERT M. DAVIS
  (Chairman, Chief Executive Officer and President)
    By:   /s/ JENNIFER ZACHARY
    Jennifer Zachary
    (Attorney-in-Fact)

 

9

EX-31.3 2 d807955dex313.htm EX-31.3 EX-31.3

Exhibit 31.3

CERTIFICATION

I, Robert M. Davis, certify that:

1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Merck & Co., Inc.; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 11, 2024

 

By:   /s/ Robert M. Davis
  ROBERT M. DAVIS
  Chairman, Chief Executive Officer and President
 EX-31.4 3 d807955dex314.htm EX-31.4 EX-31.4

Exhibit 31.4

CERTIFICATION

I, Caroline Litchfield, certify that:

1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Merck & Co., Inc.; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 11, 2024

 

By:   /s/ Caroline Litchfield
  CAROLINE LITCHFIELD
  Executive Vice President, Chief Financial Officer
 EX-101.SCH 4 mrk-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Disclosure - Cover link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 mrk-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 mrk-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 mrk-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 8 mrk-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 g807955g0411195028107.jpg GRAPHIC begin 644 g807955g0411195028107.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Jan. 31, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K/A    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag true    
Amendment Flag true    
Amendment Description Merck & Co., Inc. (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Form 10-K”) with the Securities and Exchange Commission on February 26, 2024. The Company is filing this Amendment No. 1 (this “Amendment”) to the Original Form 10-K solely to correct the date of the Annual Meeting of Shareholders. In the Original Form 10-K, that date was inadvertently referenced as May 18, 2024. The date of the Annual Meeting of Shareholders is May 28, 2024. Accordingly, this Amendment is being filed solely to:     •   amend Part III, Items 10, 11, 12, 13 and 14 of the Original Form 10-K to correct the date of the Annual Meeting of Shareholders;     •   correct the date of the Annual Meeting of Shareholders on the cover of the filing; and     •   file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment under Item 15 of Part IV hereof pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. This Amendment does not reflect any events occurring after the filing of the Original Form 10-K or modify or update the disclosure contained therein in any way other than as required to reflect the correction discussed above. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K.    
Document Period End Date Dec. 31, 2023    
Entity Registrant Name Merck & Co., Inc.    
Entity Central Index Key 0000310158    
Entity File Number 1-6571    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Public Float     $ 292,929,000,000
Entity Address, Address Line One 126 East Lincoln Avenue    
Entity Address, City or Town Rahway    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07065    
Title of 12(b) Security Common Stock ($0.50 par value)    
Trading Symbol MRK    
Security Exchange Name NYSE    
City Area Code 908    
Local Phone Number 740-4000    
Entity Incorporation, State or Country Code NJ    
Entity Tax Identification Number 22-1918501    
Entity Interactive Data Current Yes    
Document Financial Statement Error Correction [Flag] false    
Entity Common Stock, Shares Outstanding   2,532,643,872  
Documents Incorporated by Reference [Text Block] Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024, to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
A 0.500 Notes due 2024 [Member]      
Document Information [Line Items]      
Title of 12(b) Security 0.500% Notes due 2024    
Trading Symbol MRK 24    
Security Exchange Name NYSE    
A 1.875 Notes due 2026 [Member]      
Document Information [Line Items]      
Title of 12(b) Security 1.875% Notes due 2026    
Trading Symbol MRK/26    
Security Exchange Name NYSE    
A 2.500 Notes due 2034 [Member]      
Document Information [Line Items]      
Title of 12(b) Security 2.500% Notes due 2034    
Trading Symbol MRK/34    
Security Exchange Name NYSE    
A 1.375 Notes due 2036 [Member]      
Document Information [Line Items]      
Title of 12(b) Security 1.375% Notes due 2036    
Trading Symbol MRK 36A    
Security Exchange Name NYSE    
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 7 36 1 false 4 0 false 2 false false R1.htm 1001 - Disclosure - Cover Sheet http://www.merck.com/role/Cover Cover Cover 1 false false All Reports Book All Reports d807955d10ka.htm mrk-20231231.xsd mrk-20231231_cal.xml mrk-20231231_def.xml mrk-20231231_lab.xml mrk-20231231_pre.xml g807955g0411195028107.jpg http://xbrl.sec.gov/dei/2023 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d807955d10ka.htm": { "nsprefix": "mrk", "nsuri": "http://www.merck.com/20231231", "dts": { "inline": { "local": [ "d807955d10ka.htm" ] }, "schema": { "local": [ "mrk-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "mrk-20231231_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20231231_def.xml" ] }, "labelLink": { "local": [ "mrk-20231231_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20231231_pre.xml" ] } }, "keyStandard": 36, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 4, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 7, "entityCount": 1, "segmentCount": 4, "elementCount": 47, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 48 }, "report": { "R1": { "role": "http://www.merck.com/role/Cover", "longName": "1001 - Disclosure - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "disclosure", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d807955d10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d807955d10ka.htm", "first": true, "unique": true } } }, "tag": { "mrk_A0.500NotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20231231", "localname": "A0.500NotesDue2024Member", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "A 0.500 Notes due 2024 [Member]" } } }, "auth_ref": [] }, "mrk_A1.375NotesDue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20231231", "localname": "A1.375NotesDue2036Member", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "A 1.375 Notes due 2036 [Member]" } } }, "auth_ref": [] }, "mrk_A1.875NotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20231231", "localname": "A1.875NotesDue2026Member", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "A 1.875 Notes due 2026 [Member]" } } }, "auth_ref": [] }, "mrk_A2.500NotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20231231", "localname": "A2.500NotesDue2034Member", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "A 2.500 Notes due 2034 [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentDomain", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r4", "r5", "r6", "r8" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationDocumentAxis", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r9" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r10" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.merck.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" } } } ZIP 19 0001193125-24-093194-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-093194-xbrl.zip M4$L#!!0 ( +* BUANTU2$^#( "5$ @ 0 9#@P-SDU-60Q,&MA+FAT M;>U]:U/C2++V]_X5%9[M73B!;5U\A6Y.N(&>9:8;.,#,[NR7"5DJ8VW+DD<7 MP.^O?S.K2C=;QI8M@XTUP31&*M?F/_SW]\&GH0S$H:GO'(_?'Y\K0]\?']?K3TU-M1%W] M1TUW1G5%4E09?BJBI&7:Z:+/?=>J.>X#E)34.K[N:QX-B^-;PXR^D"S>Q27?.I,?<[W;KFZJYCT7I< M./RZ[@2V[TZR.R=>ICJH!ZX+%##O&^)MZBOT61]F%\=EGV*E78 M,_7LHO B7= ?NW-*PIM4T<"K/FC:."H]T+P^FT?Q(E7XV7IAG?[]+4%E@>^^ ML#SP-NJJZ\^V#0_31/(\KS(920_(F_[[R^VWN+B?73XN6O==S?8&CCO2?.!T M;$VI2DI5;B4I_J7A3G,K-%J%64Y](YSUE]J5FU6I4XU 8CX3(^14$'JH9L O MW_0M>BI+U5_KO4]U_M>'3R/J:T1W;)_:, <^??;K^+T3H@\UUZ/^Y]_NOU8[ M%8*-5.E?@?GXN7+&BU?O)V-:J4,E==%$WS$FQ/,G%OU;S8U7N-+N54]\-Z*=ZJO[YS5W8,).3,VC/U:Q+ MVZ#/O]))[F9;4N54@O]4&9:WLW3CYXX>L*&:GJY9-_#6,;[",R]_!^3*Z=<_ M9AJNIR? W]HA+ MX]@'BOA<\DY@- M+1QL ZD@7MFU!IM-_'_VE*8D73D^]+@9G].^?PF-N@PF M>L^F]PJ3)"B>/F";XF\#VGL>6Z9N^KQ_Q##A-1.:*T)R.,[J+>#&<4^I98[Q M4SVSZG@ZXS[L#@//6V99;3<34]!ZA\LLUS+'N%?++*4H77F/W"S5,L>X5\LL M=Y*4KKQ/;LX1$<]/SR,"TJ$&>3']( M_"$E=U0/7-,WH4'--LC%,RC=]@,E9\YH9'K(9P1^>F/7M/[^D]R23F3YB"!B M$K%^]>FUBT?8&$?3B),BQ7^**8$GE5->[6P]21J0:](2=9WT'17]Q?GY.Z^=W]Q-W>A<]/[ MZP_D[N+LM]O+^TL81>_JG%S\^^R?O:N?+\C9]??OEW=WE]=7Q8U.>?71_:MW M]\_+JY_OKZ^.R'F-G-6 ,9N-[A*&\^*"\\7GW[G2RTQ3&C:$[S6U=N5R++;-H$M\LL3%:G"_O;&FA[^+=KZ'H(X<:X^.:;!"1EI,;'P\>:2N;^J:):861CXC-DZM,_5A\JMB?,@1ST#6 MG%^>3V;)5DXO:D>W02,!&)-K,O*8K8EQKEOK1%^U*\ M[)O8F]X7C(4[K1_/&;?PDH'KC,B,_F!0W7&9S\TQ"6!'=ED])"^!_OVGCMQM MGKSTB\\PKMC;=Z(X_?SU5SAA-?UJPL82Z9P+G'>P,+P#N2*_2*""WEYM-=LS M\DBIY;Z^ECN'8+/-U1G3]^&3.7H@F@4[XK?KGZ]!]'#USY6'CM3N-IL/4D.6 M@5,DI2-+[=I_QP^5>K3*ZW"*TGAU3EG $+?TP?00)_TK>).?*1J5T^_HTTS^ MKHW&)^3,J1V12UNOE3SR1K;2U\?B!136,PR7>I[X]0V^(^N]69P1=5MG\@P^7KOWSI.=?QY;E=-;;?BD36:G;:FV[WS0 MW:_=&]=Y-)E'_TJZAX>UC*$.;&5*]6]73G%J?Z&N1U?MY8T#+5C_,<=GCK$" MIG4JIU);:C7?$VD=S#?LX+R!$KS:7'4KIUUIQHOY?4]D]IS&PZ*!&$0;AQW+#0U!H=G/# H M!__DP$-5?@D/9]3VA4W8N,\I;K$/2?PA=D%A#% TH3ZXVSJ\9+UC8>^WY M4GC)Z6QQ5\4GI7*J*.R IRG-Z(KI%4N;6PKEM$X!C)9W7UO_G+X04]D!8TNT M@3G^D+KDOX%K>H;)+&2K;N'R=@[5&1 S"4B';XL(NTHPE[7;VEV-7(S&EC-! MO]5W121I6$-;V2R9[+2]-V'=YO8,ZE*#C.?:QY6#?F09[^DPL>]";&03O[K< MJ#:6DALSQ455*4#FY)6\PDZXA%UG3O<38HB00M9%Q"V%C'L,&486N=#T(3FS M-,_+L[,0,6%$T'T,%K7FV#^9N^6LO#+O=&.Z=S6V']U-1O#BP,LEK)0D M5!:!S!,P_R7C:=OMK.9,)B@TA+,?Q MY;3Y#1/O9%C>FMSR]H?C_A T'?R2L F($ ME,72E9RS$@:MM19MAEFDG/SU8"O_&BP)Z+;ETZ..*6=&F8*X4*%:6YE9? MBQ976M763)*&O9S]=<2YG(NP),ZUU\2Y+%>',A1AR5"$+#\0=CS$6C9M]#-*!R1[9Y#:P*&E(S8Q8R)[NU\*@N+?G,NZ'^"\8 MV*\XKCLQK$LVJMR'!8U.Y?0/3!LWGQW8T!LG(@O%JT_$E2,ZD.X3"SU^.=KJ M[0G0=GQX\E=@HJ>1[[!L;_ W.]%SR/6&1N^E$R3!?I\?7F/V/!9\HP"IIV M64W23>/UZ68! _WN6('M:RX+]G3SYWYH=)$TI_EF'JFVMHE4GX:4>;Q.T>N! M?,B);:B%>0DURXK(-4G'?2H*0,7K!I4;\-9^8$7QI@V* AR1%<)2?WCD .J# MW9YX@3XDWA"Z CT7<=K^4/.G1_&D>;,LQ[XL!G)XQ%(K'BB)T?9!<(!"_?_" M6/!+K#Q\$[LB*D/9PV,]83W%$+.N1 QMXFW=WB"2L/ $ "@.^YJ_0G:3II2Y M-BTP!!\A/[1.BJ$HM$J1@$P2>'T.5 MAYOF=#X/$>]2[W#K.#.QGKB<@E'S7"= M)W\8OJ[!EDS9D)GZPS*?>,BML&2*(IW,&SA[+9^$Q186F-^_L"#NPZ+PG+Z& M)4,%K? YEI5^51$S*P26I)12RR#6?7+WE]L%N.PW.P54HA01L+JAV(&%%NS0 MQ+=$WAGW##CJP7&7O3)JQA+&:F(,J8N:TD:QIE(Y_9;-XK-6@"(MEW%ID*4MEPH;>D_J+!^RJ] M0?+%$^M=O.4]:]4W1+]W?.OD7XKV3_ZGV!DW,[8% ,7Z]27P8/J]917*I5,* M-M7Y*05+#EN&PY8)S,M'$#EJS$=H%]GRWIM0==B7GUE7SGA/"J?NQA+4O2"T M=D.ZT> %9>$(1.\E[=UHSV!6#-ATT? -*GG@<44#ND=9#N.,7(N@JV!;U@0; M9Q>A0+/$AOXYJ#L\FA[;Q&W-UDW-0J$%,VE@8;PZS]!'^$T3314V3#BR@>M8Q 'F2JQ#K-6Q-)3IV6Y( MC43P])WF]C6HNWK];-$),_X>R$WR6^VN=E8C;:6%D=:'./IXJ"(VNV\!OR:6 M?&"Z(VX,&D,'-"P$5,).] S6;2TP3%]T+ES:N>Q_J0_<'G[!<7OQW.6X)G9Y M[F_.3>/^)A0W(%[BIB%W:M:7C(B?BPU)RHTIAN6OX69T9_:PS-:MP.!'L?QK MPO@^L)A-'A[ICNOR[N#W$;)<%\WQ#M+"H^D$GC4)22&KU87D$*<%M^_\D7^! MU9]%C6Z$+%IS-X4M!"+$9;9R#L ZG_QX34(R2JPRX]/(0HMHI3O,K V@9$T\ MDV.-C=X' #Y5O K;8'L!M3V.8F@EAE?LG"EJ/4DW$:K19Z!G9B=W!@-3IZZ7 M-#>[L"\](IE%71"[3Y+6"U=/N#U<:4@U63JORL \4YM-.L7N%JUTECW4&U++ M"L4"6<8\'YC,U@*PLO+8^ M 63MK=K?>%(NI!E^*R)^>CGNF#B!S^1)A R-?>$7S0XT@ I57+%W'*8K_,J. M<*"NF8-7U@1KX8ZU>QU7.C774Q=5$[R>D;U)WO0('*:;H')[GRN75U]!VP35 MAC+S<'))[&!4-1R6&AP+IY:E4SE5CIJJ=MA(N3CB$TRP#]\:7I_?P M .B"\(.H0WV^!DLL$M NVPLV<]0R0*$#>N6%D&.37P*;$E5B!* 2OD,Y7$+1 M+<=#8AD#D=.9LL?D;XNHY89)MU\M1YL^ 9RZLGV*./!FT?4IHPN4T56.NDKW M2)*DHT2:S&5I8VL3/85RG$?B-(Q@? (_CS^$)F;KOMMJW +A>)]E)2.6KF+KS MF,_V93YO-)=91+[" X)7+[YYT,L*TYQRX6[047JC)@H^60.TD< M_C*)4/@>^O8%5WA)093"-C=&SWDW2$F?+0F6SW6>)^0NU#XC3SUQ4]MW2ID! M"1:8B69#V#E02>0N5$RN^*Y-.%\H'2[P':5<'?/XA2+2!+[0J ME!IHJ,P,^!UO>,D:87HIWZ68UQ0W8V>?%E3"VN+R\7#HH8F&DPHM! M$>_JFNDE8B20(:>&1%GZL@A?^A1(&?#%>@)*BNZW&D90Q*]?_ZG+_CL)AP-2 M;N)"LWJ>P).]NX;]XM\WWWI7O?OKVS_(U?7]!5E*G8ZNLCT'6'+-,8K,.3WY M5*DU=[*6TKP:>34O=@N+@(7T52SD !%)>&.=I;RO#@4"HGT]??$E7JR$VV7Q MEI]H_XV / F6_# IO/R1CT>HZ6IJ(-= ER:>8FRNF^$DB>[FV29P^FC?12N# MV'E:?.>ID?LA*\EL;:87FL/9SI!UAS(.&EZ)44/1)^9O9IU$5V+H5$#]TB81AB(&\HL!EJ' M(E%![B07;/GAX9K.R!M%V&)R(T)/AP5"1=6:'$W3EXF1$?S8#?D_6M/C%[TB M6UNO-LNQV%#,Q9_-CW-=$D36XB5O!F4,F^$;%WHU9M2R8N#P6E=>+K4SSVSJ MRUYYJ2$!DE#PA.T)1'H/ZC@B,F"\K,#_*L-4N1%RV^L!V\J(%KD6+"E(EVQ4 MLM%:;+0:F4;F;>;O$2FJ*'YPA_V2BDLJ?D4J9O&;Z VFXPC"ZRG8 9T3N'CZ M8NOF&.AYQ@. 46O\/G8)B=ZCV\#0[*->PP3DE/##W9IP[R$R"V;C&]+O9 B" M(/PY$VRWD>-ON2GV'=Z=)0)J66(#MH52@X>ZSG7H427E!1\M>*-(DE);BN,W M+J?>IU?'<&@87L\]A%!1HH_'A. MJ?4!PFOD)0'?&SH!GJBBMX?&'#F@,_\-;%Y5I,J^PG35TKXP+][8-_/O!_+A MPZ=Q(>8U:&D,P)G7O/:!8!=>T\;V@62.. .JIRQL"WGM9,9BEC&8>[9'LQ-[ MVV=E5) '>P-(($C_1L/T4?G[R@\1/Q2[)/P<\:6> MH%18+W)>L<+I.?F$DS7/XIX\1,)RIQM=NJ7&NF2A61Z:BCE*U9** IKW)DE9 MRY1J9';CE>CF%,5?8>F4:D4S*&LAL660]"9!,C>RY.Z(&D=@J^ZZ7% XRFTQB;9!>8-N:G[@OB,2[!9)@A_"T_'LL[!.8L'FG]=KWW6>=.[OF %/(6+BF/ M=$A9U!>(;/R\H:-(,C]PF);<4I47"*%%D0SKV(K'!C42H6G*S2:;^%N;<;)) M9!NW!>:SW7'T(O?'JU'C0 MW+JA^5J]5A,_YO/_&H[^.;.0*DMRLU.7)$EN*1VE X.5I%:G*=5'[H\J1LO( M\%,;^J.?S$&GU:;==K^O-VFCJ37[JJ$:75GK]#5);^CM/UNP^S=DW/5KTTCX M"MY?\PF398\SD8.XQU(Z9U4KD?=MH>><.2#:&"K3D?&.5J5M?#BD[":R,"*' M)[2([=T)@@M37+\FO;_%\H713)B_3H._C-!]R A@"=AXE1-R';CD=TSV(6Q+ M48J_>%UP;'@Q"85E=R: 04UA\N>2[J1G/!F>1=TP M1"L]#,R4]*B9%O>.LC-7](GV/< $HOF+D>(5"B#0C# LL :,5!?YG:JX*SV: M]*FN!Q9*^U48?95E8?&@C$&KSJ :;<\9OPH8FL[GM,Y;91V(,C[6:U/-I>+E MT"/-8#P@W"R!6P,+%=G)'.92C%9ZEC[2"]V*_=EUY0;Z)PTHR9U7ACQ@ MKBSNFYFQ@6 %1BP7(-*P3/V<1D*:$('C W1M[HL\NSR$? !4YSR%)![Z\^-P MHS&ABRGO(^RI+,L9"_>,&(6PL')O#.,TD3X12C1C2'F:-"=N<,PRP.A4I'## MQ&XFN_0 Y,L89[$?EO;$IP8?4.@[AF@*+K)HE (N]E0=@MA$/9_$N3MA%!'$ MLKHPJ>"C:2"Z]>E0>S0==[LV'!R'B=5&[N@A2?#LDSI&>/H^YAY##WT> M Q$6N--\<6!6PVTA%#9%N]X6[#53NG"I-"U2FI1<2I.\LTI3ML/*EBA%202( M8"&E*:3R5J[/SEXR%#^J]SS^!C)V3^31G+YYY2X8C3!S7>J[S&-[NF0/Y*AK M%F*0+!L6\KD8'/;DXAK4G@FYQ3+3%>&+1Z]&;JC+9@H&FEW+S[A+,M2_L32[ M^H6E5.L]X5:0_85$#CUR 3/O3UXNSA(QH-[MZJ87B9$H?O\.&P_>$I#UM1L8 M.WZ/>Y_X#7P'%\&X:08@615N!1&26M*^SP/D6J29I@7WNQ+3^,_MB_95X2J:=\UL[I([6<,?LC_,?\51ZI()#RZS+9FHAL[CV=P-\70MT65:2Q'DZRWK"^;]F64ER77L3,F' M&SLER#@4D$7?R^,9'JVT?X*YFDLP5W96,-^LN^X6"/A)ZS\S9*"1)+P).!R\ MDQQ\:#CJQX-WXL''EV[LHP59:;S2L:Q0!E*[(>H4J=.R:QJL3;93?S:AYKF5LF\0H89&+*.)%>./F M:SB*OA18O*"O_%(#WIPSX+_C6WSXW[[#?_?II[Y;/Q6WX01C;JIB%A%@=_8N M>>%!"$#L108(L><'VN%J,[2AXFM,Y<*SIW^QTM2H:M V$"OO63B%X33@K(CT M_X/D!1)\?K- G;U)SFG_=>9T2XB4#Y^.0':*[K.,SDO%]9V.RTJ) SND8';D MQ#8Z]H9O;/%EF+%Q I^PK8;/+7T.S64S/1B(>^I8QA,K&-D$J/N0?TU?9TDV M%N1_TM?T'P^N _-0%8J@KE,Z&"SA4+T=#J47\P62,9[ G# '6DQR!#6&@W07#+FHH#&59<-R6];@7M+,N/YV_%K4.[76LV-N$ O6-^UQWY2%;4([6U^[&!VXZP MJ*R]B++OP8]?^)!%=Z*],H.54[%OM/%RI-[S4AIJGO"AG&N1%Y3$Y1;,. ;P M,_]RBQQ8\2I]V' "L7(>2ZI< MLR"P=!\C$!N+S^P7VB&X06@+#^9GSN$7C>22'\9YH34?3W#'@:L/-8^F[T%F M41*IJW;C0T9QZAB?*\:GF5Y\/%R-E$FF7Q['9WJ"*:B*"',$ D#BP4)^GCZ,"X%L6L9'LBE)S".45Y M+YQR\2PXA5'QLSG2?+S82%:.F@WYJ-5H)=@%?OFNR0X+/$8X>!DS/QN3C[JM MUI&JJF0<>SWSKXI2!YKG!2/DG9$&S00C,M8F>%!TF& P?A2.OA?C)-&?.\,1 M789Q:J1G>1AS) 8E-]M'+2@ M7&W$FF]*(-XT\E4ZGXW9L2OZH40^U,(G.A4"+%P9TO$ "WBU##19V9^MDO:BV%JB5&$?FU\? !7'CXLSCLMG+D;5G-J K?+.^T-@P+, M!.D4./5)BIR!SS+8;[.+>>.R8MA]*13&;^[!//9B>SZX+OPGZ(-*&LX@,^]5T1ZQWR)' JS = MZ&P3QVSK&E=]%JI18>":2ZL]INZAI8Y+7S<.M#IAS82+E;N343#1T'6"AV&( M9XP*4A7?8'B^$=Z-3E=KY=51<">C6I0RJF6KDH[]7N8<6W-';>7:49L[NZ,N MGSITB5TU[EJ^^SO?"Y&]<":PM#F-N4MO%1'-T$PZ6,5P](#'I:,!BU_YK7D MY:[/=T\06/L0O-M"N5VUUX3(=NK$-)VWSF8 M)R)'G7/%H%K,386=[L?-9 E?,K;G) -YIH,55O3S$(^8JX>?=O4X(>GK2ZM] MC-^?ZGX!L8VJW%5EI2EU%47MRNVZ09]YLM7*Z2WU?&8HPL,(;O:AW( 2&I&$%8@=HJ6V M=H86!M5%H6-F24(HFHH;F3YS.[AR'EE<+U'13B%U#Z.DFY=S35>^4UP/(IO+ M6>"ZW':#64G01KZ<6-F)L^9RZ30R]Y)#0X+"\GPRZ3Z#;X6 M)8\N%"#H8("IDQ\I^:[!L%:J5%&8$539?7!98PZ:? Y*:-DLM#1V7[BX9*<8 M@4N/6$I?0^3FZ(U=TQ()S(\(C!7^[5/_B5+[97G/D)*BDV<2S/[754-F7TY'E75JMI5&]V4!US)H8LY=.\V_U:CV^9[?[;33#-+&AJN==]95>3E M6-+.R7P'_<,-\A_?;._HV%]=E,<-EPUL668&;FZI';7<BV2]L%N&BE+Y71H*,6*\]0P)9 M4>16JZ/6#57N*%(7 4%8^.Z'IKL:'GS7)JON[@I(''FA0-X,%"Q]4OQ_(>?_ M'^@5F ]Y$L)'Z(LU!BW&,0BSDZRAEJOA!)5J^8:!H;F_P""D?DF59%5I2?5) M%WK;H<^/C2>A !2[_RLMMMFI4_:!8@R":3-"]<9B?IHSU@1T(V'&A(0)8,8 M@)U4I4V8LY9U?$DYKVR',;VP[2Z\VV,0+*"/D('G?:TX];/$>84FN"_)UZI39R8LU;'\:7 M6%-BS4*LV3N?WB6P1ED':Z19Y% :/,5H39V&&[65$U.4$E-*3-DR3/D?6=K] MX)TU;"JJU)';7;G)/LMU:^3^ ,VZ^:=!!W)#X]A1G.7CXIGJ 0OLBQ,(LQ2\ M&.(C A#Y;9]A6'(<"OA+8-,UW!&;;Q8(&.8[(G*C)\" A56M-AB5CZ9$@DT@ M02E0\ !AJ0D"A2PIALC />8)N&G1>#"3X?LR<@;PF2^?1\F=9L&VF2C*\**7 M (O;6;!8S[S(6*Q[F$>\0>+90_%&[A8BWK2$J%2"V@9 ;9_CI%Y7O&%G$EE7 M(\R7;TJIII1J-@T 97@4XD"C)7?J1D/M=-M- Z4;N2O\F(3;(;\_A-]91'SJ MCCR1O5I6R5]12!!RK\8WV(5T:CMV%;YIF0.3&E&J%-[ QI>O.E;2C8,0[D. MD5$S[NZC3*,4(M,PCVRY],C>"*3M]CB&3FXI':4C*0T MTY38O#6K@*IM3DL(<@Q M]-*7A;?VS@):3OMZ>P_13"E&%V7Q04H1NNANQP-N(LW$942FW\;/,I36YBW:V56V[ MK;W%M[T\F6\5>#)?YDW:#+[M\!!X_FI> MCXH8%/3-9?V"#4>6Y2,@)?R?>$/-IBMEMFO=\@ MVNQSE$?&(8"L5L? \1X=\Y"/PD4OEL!K/M!D!GL4!2W=0ZQJ$+@@$[@1C &P ML*@X%&B\Q0R&]53ED,$/>-_6BYOKBMX=+=.Z(LVT7D2,O+1TZTJA8Y=RM2[/ MC'W=ZT04>>FFBQUX*U?K2L$DUPAO>45&6ZX#Q0Y?%?HF;^CBJZVVWY3' M;SL@2.Q=M-CL19FMJB0UU':#WV-Q2WW3Y68"MK>'+'(.3W7?<;V";[\N-DY4 MX7=MMO)K(V?3EVUNZB:ME<>F2GQL!9AB5%'3LIBBJE*SQ)1E,:4,UU)X8@TU M3-0%#]M,0QF@%QRFMB@\N48$5CQU!C#(C3;AULY!#%Z"N]GMV=3VQ(W;"])K M%*3(@-R65VS:2R=@N< <8J7]93,05X9LX;&7),F-NH;>(\ 1(^"7'W^R *[. MLP/@X7*(N\:/Y!M%7Z8-I5?_A=JVB:W\1].'P#'QE::K:ME9,"[:.; MI=PIT ^IO-6D648ME%$+"ZO9M:@%>8^C &>S]\(>J591U)N*6UC2$0Y$Q.UW M?5O=526YH>ZEX;3,(KS]&L >AV%EX5E5:3S'@.9Z00:>H7G3-75D>0YM@0U< MG@ULNX!-&[IDL,2F$IO6PZ8RJ&K6 *LT4.!28H%K65E+V1M9:R_QK+2V;CV> M*64050:>-1-XAO)6;EE+V259JUEB4XE-VXA-^QP E>&)BPZ'H"2L:->2=E;6 MRI^N;R_OW"M= K3'Y+ ]-NB$I[>0A8PM'VP]'>14\L@"-F M8Y>],=5-D)6HC[PO#.WW$>;V'X?V..(B$X>F M;>,)E>UV@:JV1EB1*OB%"54(%6=#TQV8Y.? M UGNZ%M+^WK);1M/[3M<:1% M)K2U$M V3D-;4MMCR:1*;&/8UBJQK<2V;<2V/?:)S\0VO!I'45<\.U3WZ.RP MH+C8G0(TM<"[YQM['V76*J/,RBBSA=7L6I29LL=1&9D[:F>^ML!DQ.4.B+9] M.RPHZKK<#DOYOE TVN,XC$PTZB;D^UDT4M\)&A5T5T.)1B4:%8E&ZAY'462A MD2I51^X/G9DQ'Y@5$Y/6O%K.FI3]-$Q8LW)NO ZW^>6TC*K[>&5X:1G=;JP" M*I*[W9,RL"()5XI<]8(^+(0)!&N9GJ]YSD!65 Y7=^$KDQ:P$FI2.PTDT4:NZ8WN@ZS@#$#\HW@P%?XB$?6?\%0+)9?Q2W*5$66;1 MH&^9.NGINA. OF0_D*\F\&@^L"C(J;<$BQ(LB@:+1JT4/I)PT9"K8^>)NLY M@]I=FTZ$PPD^1)SHB<L,.=ZP&\!<$E%Q+A8I=(5"+1MB)1*:RDD$C98B3Z:MJ:C1&2 M*R-1*1.52+2U2/1^3*U&1VIWFTT# 47=#NR8E6)*JER**M]/J'Z2*AO;096S M.UI)E4M0I5+JCRFI#4^Y\R7";"G"=,L8Y@2^=-O5$7*I"Y09C/'VW;%CF7IT M7(Z?F??OC>OHU A<&J;$"LMSKQL1AE#]HGG :G+>LO@J!W$CMV.%6Z7L<+O M.59X7I!O4;'"K>V+%1;X*$0W23[>W"96W]C.E240E'()K&;M\NINUZ62?W^Y M_08[KN>S8,AS1P]0.A!-W\/&:8;O#/$./L!LVHY/M/$8MU/39CNLB3BHZ,7 M2/#N[)_O@@3OM6?'=D83$"E]D$%1 KW3AW2D1319TL%+='#6^_9>Z>!,L_3 MXEK)-]/^T0=EI:2*I:CB_.+K>Z6*M3ZV2'O+1 MP\WMQ7NEAQN78HA9N7?D)HN==V,X<^ %N8$Y!*TBUDS.43/YBIK) 4L!XZ-9 M4_-2F@<:3G6810V>&*C>Q&9.^3!!-!\BNA59OI(DL._!^ M4 DBBM(XV74BP'-= !V")Q>P8[$<"V@6$9?QDJ'VB!85"E0P,AERC0/7"T2F M;(VX]*^ >OS0 ZAH8&) -9X'^S#5/J,7@C:=I3+7CEGP=4A?ILWA$C?2(> E MZP4__/#H6,/C(6O"3#FLQW=4#UR0SF$^$$TOGO4ADBP>,8U,C^W-R:Z[2_F5 M*8U^50D[%"?G2K05M=/3V0F7W%4;1PCOVH@=^BQBE\QCAM:=PM^R]#%*T?%R%AU>/P;JX[:C\0W1HSXWTV&5?)UA&@4AXG>@:Z8' M%(>T6GNA&: )RR*#P+5-;P@TJCOCB:!K$,6T!Y=2/FQ6Y5*4 S^"TFOBQ&@7 M3[LZY6E7?-JUL8EG[Y[X2/N.962L!#&-SQ77&7%WUS_;E=.[RY^O>O>_W5[< MD?ED(2MSNL=:,%DRB_RX<)- 160')'33%2P";"-\AT)G(!0'Y.:!<1AN%0O! MD%>**398CD/$B/)U=B%/H@.,%7P I@.&;]/AYHU0$< K(A!%2_ M:G8I8)3#*XRQJ;;*+.::M7-$K6/2&[NF):9&%H?J4TTGJE46">=2&AV0YF.) MZ@W.91NSQ[*_9K:O.Z MQLWKZFP- P%2UQS=G[V*.]!X*^4_U)2_3/(>2R];/!ZD6CF]O?YR<7M/OM?( M>>_WR[MW/;5Y#^03$YJ8L@4L%^-DTQ.(V*+^')]?W_]_5BJM9L@I:9-0#D[LWJ- M=:].?KFXNKK\>G%+_M,[^V?O]H\Y-++=;/2*%9[^0FW;Q$2N_]% XG(G)5/M MS-*M'\MV$.:D@JFL?M5T?RJ4+<-:M9[M6OV>&?CCS+.\?]?U(>V_J MAR7:]=8!3"=P/X-S,PUFP7*B/-[ZH:? ??AYYDV4C'&JII2M4VG,19F33*EC MH-_#%%/*)2TMT_4?.O\=BV5J?-(^,*X R=B:8PZ:R";*7'1N.2G7C*M2%,:P MD%?0KE="2I$?3(G@4JW8O]08'=<)R5FV-T*6TPKF= =+D1.L9,_\F_E$*6N< MBF4ZEO>HM0__:G]JA'\Q?0+RN MP@_!8/D#O%K14L*=!B[9LFK0[T6X9LD>9$JD =^&\.A>-RXOO1#32 MP(>4;"F4=,OHCL:(@U5@YY3'^)4P%]H[OJJ*JQ%(@3$: M&P_,ZV >OK19RB15JX)$U.!B5Y("2PW5OTV]]K) )/W>'2VCIT/J=R0OKF J MM 'X/-*NL$3\JY48:^"0"ODCH7P/3P@[H_&:#@Z"M&QC@5%<2(@P%V$YA MPV6YH5!)(FFCF4B (!IL-(9")21"4PDBQX:7HM]K'+_RX#2B547*?:US3IYH M(_9+T@IM,:+!FEG]&-5%:H>(E=$F1S>.X0@EIB6@_%$*U:;^.<;O:$G;)#6# MG%49)3'C:]@QF2+#JJ"1[':Y0&@B1IY;#(MAM3_508.?_;Q:+N(VP"Y*EK7] M-QK >#B^/&^,DZQUX;/1]14,Q3JD:[+4\]=V9AY,O=GL?F%/_?G-1!DJS7IA MNVZW?O3=\':B7 XO%'""I>LM&W,+X6!1<4+/[,6]9W07_TOQ7(]Z!.,0KB$M MK?;"[0I_O,"1I8?N\<9#.] .S%X0CCK'+^/_&G=V_%F>5.HH%&1-U55)R9/* M>,5B:I"M8#%\)X77P5G.WC@%=8Z]Q= JJSI!& 9WQJAXADID".*/8?,Y;MV; MJ=[,I%?Z^2P^RO,KI,$&_7*GSC5[F^L\>%S:"VL9./@F:VC8#_[][TICFA*& M!Q@^@&G*: +>,XTVDN&K*4@2AF_)YJVPP#&%V+D\;6;\JY_BIH".IQVTMV>? M0YOK]1$*C@D !$ !D.# W M.34U9&5X,S$T+FAT;=5678^B2!1][\3_<,.FYTE$W=XO&DD0L"5+B[%)S\YC M"854&JH(E&V[OWYO(;:.T[V3268G61.5NMR/#&\LX+-%N= Y@32/O$TSOW"B,5A/MXSR(?0T>XD^A/]$*QJF> M4[;)I;D0=4D*3<5 [PI3N)1+6MN6%SP>_7H-X[H4E3FLY"UTZ[604I0'4R:XU!OV-S5'IW5&2E;LS9B5M($%W<%* ME 0K.6%PMYAHM<*IV=;4]E]RMF82%&FPC*EM&4O%^BT$H_%WA)"TFK087'\5 M![/ =>(@6KR">%N%[X+!#OK@DEJH38.0R23/&"W2?N\JH;5DV1YD3J0)[\/X M]1T4G4GMI'ES_8VH1@,(("?/%&KZS.B.IHB#->"4E*?XE; 0@P]\W52W(Y " M;U(@G&])@0&5J"4(#C-L/K!FT2)^;;6<2:HW%4FHR<6N)A66&NI_6H;RLD%D MO:M[6B=/A]0?2%G=@BL&?0AX,KC%$NF/5F(\@"EID#\2*O?PA+ +FFYH_R!( MQS85&,6%A 1S$<81Z1ZV7-9;"HTDDK::B0P(HL%F8RA41A(TU2!*;'HI>E>M MXQ<>G":T:4B]5SJ7Y(FV8K\F;="6(AJL6:A'2151#@FKDVV);AS#$4I*:T#Y MDQR:K?HYQ>]H3;LDBD')FH*2E/$-[)C,D6%3T40>=[E":")%GL\8EL)Z?Z[# M /[K9];V$+<)3E6SHNN_41_&P_'-96.<956%+\;7%S T^Y"NS:)FL#,-?7#] M,'Q8.FZPN)MH0ZU=+QW/.ZX_!EX\GV@WPVL-IM'*\U>MN8-PL.@XI4-G^>"; MQXM_I7BIAQK#.(@5I)7=77C'PK]=X]@R8N]TX[$;:@=FKPA'1\?/X_\8'^WX MLSJK=*10D0W5US4E3SKC#4NI29X%2^$;*;P-SI[NS7-0E]@[#)VR^C2*X^C> M'%4OT.# 3.&G8?LY;=U74WTUD]$8;\WCDT0_0AYLTL]WZU*W]_FVH:ZSBL)@ MX4,8Q.Y\%OBA]_\BX+_09"L9OGX>64)AB3,(H7&)[\J=T7L\TWL8 M!_#?SS:;;'H,HVHN75T M7,>1"B-"I-%RB;E$*HZ%490SO<[EG_/'.>?S_?-Y7M_G>;^>M9=K(D#!V<') M 0!!$#@L?<#:(+ #0,C*PF5A"#@<+B>'0*+Q\F@4"JV"4\3@B022&I&@JJJN M9411)QMHJJKJ6N@9?&=L:FI*HEC96%*W&IF84M<_ >7DY- H]$9Y^8U4#54- MZG_.6@. 10!$X# $) ,R6!""!=>: 1( @##P:X _ LI H#!9.$(.B9(V5"L M,B $(@.%P&!0J+1Z5EH'H%@83L-XNZSBOB-P\BD\-3X]#Z%I5]ZX@=XSIV7B M'W9.#JFDO%&%H*U#T=73-S4SM["TLMZQT]YAEZ.3LYN[AZ>7M\_^@.\#CP8% M,X[]$'XZ(C+J#.M\0F+2C\D7+F9D_I1U]=KU&^S\VW>X!85%Q245E575O)K: M7^N:^,TMCUO;GK0_%_3VO1"^[!\8'1N?>#TY]6;ZK?C#_,*B9&GYXZ=U%PA MP#_SCRZLU"4#A4*@\'47*!.YWH"%PC2,97';]\&/G%(D4^,1>+OTO/)&.4T3 M^MP&_[ >I)*6Z:BV>)WV5?;O8.?^E^POV-^N 0 - :7'@V !&K 4W=%VG)G# MX+CK9X"'40K6&-8<,\!;K%,9LV02&TS.B+ GU)5@;&&[Q@ZREMS%VBV"]H8= M5@HZ4;:%J32D!(-:9H\T6_L_E02ENOL-0TCMCN_.#]K%1-YLZ,.^:;-Q/VP]G7VS9_IJV1/\WFT? M582,HS.MW/!8E%E'J5W3V\?3 ZX56<;WPR)R1K@NHH$I\Z:QVX19B@VRAN;<>+O M02>A?.FQO1BZS:G/TFW36OR^H3 ]FG,^KJI-=NQ%LFT&;^&[G MYX:N3FJ!+#?^H0*B8:1TKI]83[ UU@ ;;$"B7[IFE BF#>7&>!T4C: V)YD^ MOC"!&^H9\=[ M8C^&Y]Q0(ZM"WUZWT24LI+;],_OZ"^/'%%^&ZT#KF&J L&6V:L5H1D;KG%^]) M+AHIT=;Z?P=02P,$% @ LH"+6-R]F(0T! *!4 ! !M'-DS5C;;N,V$'TOT']@]:Z;W:1K(\IB6S>+ $E:I-LB0%$L:(IV MB)5(E:0V#HK^>X?4Q:(C>66["!;P ZDY,^<,18Z'NGB[R3/TF4K%!$^\.(@\ M1#D1*>/KQ"OURG_CO;W\]IN+[WS_/>548DU3M'Q&BZOK._3PX_T-NN9*8TXH M6@A2YI1KY*-'K8MY&#X]/07IBG$ELE(#@0J(R$.P_U$1HOMI$,$41G'LORLD MR_Q)-/D>_1E'\\ET'IW_A?[Y]?9?WS<2%'FD.48:RS75=SBGJL"$)EZ'+*>2 M?+(D$&8:PP_2R:A1=25DOJ K7&8Z\?XN<<96C*8>@ORYFN?RTQ<#6:2#>IH& M0JX!$L7AP^W-;U9@$S)CW(VY6R)^W#3$5$J?XUQT<)76"TMM#;8A6O 1)1=16QR6EK!\-!@=(-^2Q'VDL#I1C1E0_UIH5KN.#CJP!P:L_&)_"CV)[%G#C[F7&AL M"HB=%07C*V&&YE#,32X?P N9P>_WUP/GV*;\DX!2YR$&RU,-VR@IA3K%+$<, MQQF*TH(ID@E52@H3B[X(=Z&-=ZEH^@N_M&-X PKJC=5K#DSM54/Z/+8!Q^$) MSDB9#1.$SKJT(9J*@ON+W<01!14:@:[:%LMP]/S@?4^-!_W%7U5V61X M>6@VX$*SKRX1V-:')K)S$O[G=,).J0G=(@2Y"*D1[^U"AOZ-JP;F1A ;9H^+ MF?F-GV\>^?'$G\;!1J6UM@,$;+,Z3$#C=Z" _O9B)'7C8#C/QK -M!U]=*H1 MU^L3TDRKYHG=E*.3[6]D]DKH)N\79T'&>W M!QM%NG6HAL?1;ONY4:0-W R.)-SV>>,8&[P=C>9\V2K:(LOIVG24X\YP)J7C M90[RS!2/^/PD"2-+2(=>GTR]OU$>*Z<;Y>=MD /5#=QH1FV'!FX&HS?#T)WD MA,IJPQPN8/N[# TJ^)*GG:N.AOJCB!61>.^B MX"R*[H2F:E%2\P7FEN9+=.--7GM3 ;8C\ADXK[?Z>ONKD'V,9F$ MU8F[_ ]02P,$% @ LH"+6)5"GA=< 0 DP( !0 !MOYR\X097$0UF7]8HQB)+Z#, MB=CO\NW7O"U!+ M P04 " "R@(M8^NO-'J4' #H30 % &UR:RTR,#(S,3(S,5]D968N M>&ULU5QK<^(V%/W>F?X'2C\;L W[R#3ML"3I,)O=S23I>SH:80OPQ)886=Z0 MZ?2_5[(Q8.)K08B2ZE.(N9+./4>/>VS@AY^62=SZ2G@:,7K:=CN]=HO0@(41 MG9VV,S%UWK5_^O';;W[XSG%^)I1P+$C8FCRTSB[&GUN_?[B^;(UI*C -2.N, M!5E"J&@YK;D0BY-N]_[^OA-.(YJR.!-R@+03L*0KW_^U&+!U[7=Z\E_YRG6= MX8)'L>/UO'[K+[=WXODGO3=_M_ZY^O2OXR@(<43O)C@E+0F9IJ?MK4&6$QYW M&)]UO5[/[Y:![2+R9)E&E>A[OXQUN[]_NKP)YB3!3K3*8]U*=5/7SGW__GTW M?U>&IM%)FK>_9 $6.8E:7"TP0OWGE&&.NN2XGN.[G64:KG')F%"LA]GN8- M MWFPKNCB+R369MG*D)^)A04[;:90L8I5A?FW.R?2TG? [1;KO>L4XWX^8G _M MEFK_R_6XDD]">'"7BZC>[:XBNVHXS(-RQ-7+[<9KE!$5W3!*NJN8+H[CMA8B MP%>9KB)JD$//>SL&CGQ-J)J:3DBF.(O%,X*KZ?N9H+($1]0,TE771P'-^W 2 MDDS4;'D^E-5^CX$XEVAXD$V(LT[]&8'6]GX,7,K$\%G73=EA#DK.SHA&:B^[ ME%U5!B%+06A(PG(8A4:_0>2;-PLJ/<5JNV3\,=ZT3#PE06?&OG9#$G75_J1> MY!M5(3Z)4'G@C.F4\02O$).Q($E:=ASC"8GSX9"N"7JS(N"%L-[BR48P/-H6/)/\9*E,@"U41UBB9#PD7%8J+ZM5>6FXC Z86MNM4-^(<@T[ MEU;)C2[[J+B;3+TNW@OH:/__1C2J M5C7&"*_69088WR12SWS_RB:H+Z9 T&_-6EXWD>4G33JI7EZ M.?7ZTKSV9O;<&NGVM+>':/7HCH&\@(:]SJ#7^\P$2<\RHN[B?*H8OBW^F\)1 MW]")76="=7SO3/,JZ]HLZIE^=SS3;N?=V\'6H&^:F0;"4?^-34PW95'/]/OC MF?:J\OJ:.0V$H_Y;FYANR@(P8[WGF-3^MKZ^=E+7AJ/^.YNH;LH"H/HEC.^M M[%%3]:L0]"K3^KC;$B5N@-V7L*]#2C,<7Y,%XT+#\G8H>I69?1S;N_@!UE_" MR]YR+&LN-?)>S.^&H_4>9Q']M4D &CS=U>HU& =3/LS"2/8S%'*S$WD2%S&> M 2K #=!ZB5J@@R8-0(FG6UJ]$D.90*B2:""_$H-<,_)2/K6-Z*Q2YANX+&"5\-P& ]X-LYA,W^BO"(Q:>T_ ,"UT54XE%[JM8 MS^.V^,<9 -0?Y#L/I/Z#W*A M3^)])/%S'(]I2)8?R4,C\3NQR+6HA(1*GT3]1123SQG@4^O"D&M1 M%5\+'N#:I"T=99RK0SU* QS_03!OWMRA<+1>BQ9PWY@$H(%)\UK,A=](''^D M[)[>$)PR2L)QFF::R0^T09Y%ADJ?"2")26=;@/J5Q1D5F.?KE$,?3JB-1>M5 M:XT$=1D U)LTM*NCJ%BCA;>.Z.Q&^KNL68'Z)LBSR-1J$P'T,&EK"TPW<[E M1RQ98-IY* M_@3'\8.19YWNA+ 93!K@"J"1?/F%WTH;LH\(FVCD6U?MU^< "&#>_:[@J%*7?.%7 MG'V-BN^+:578:8)\Z^K]AD0 /+@FD M2IATPC;'5;MAJ&_13?I:\ #7YCWJF :,+QC/D>=E MTXAE5/ ';972V!+UK:OB]?D W[,R[VQO\7(L,>#W.!-JAO74W? ME D@B7F7.Z:"Z8#*&3>!H]8DJB-E05W-W,LG>&73*B?LE'5=//# MR(:&:&#=.:--!U#(I#TN#2PZ M?@[+"I#-I-/>+/GRXS<7\HKNEQ]VHM' HCM+33D KS$SZ44<(H/N>XOP58\ M&EATHZDY"T"&TI9WJ[_;DU]2(ZB?$OOQ/U!+ P04 " "R@(M85R7\"G8) M #F90 % &UR:RTR,#(S,3(S,5]L86(N>&ULS5U;;]LX>?8/\#U_,R M ]3Q;:;;!&T';BX#8](TB#.SLQL,"EJF$Z&R:%!RXV"Q_WU)RK(ED1^II$O2 M3W6D\Y%'YQQ3I&B[;W_9+!/TE; LINF[SN"HWT$DC>@\3N_?==;YHONF\\O[ MOWWW]N_=[J\D)0SG9(YF3^CL8G*%_OQP;XZ MZ?4>'Q^/YHLXS6BRSGD'V5%$ESU^_H^B0W0S.NKS/_FKP: [7K$XZ0[[PY_0 MW:!_,AR=]%__A?YS_?&_W:Z@D,3IEQG.".*4T^Q=I]+)9L:2(\KN>\-^?]0K M@9T">;+)XAKZ<51B![T_/UY.HP>RQ-UX>QV[*M&,KFYP?'S2NZ%C:+]8]'^X+5H__OMX4L\(TD'">3O-Q/PIXX7A,6T_EY^C*RS6J_K*,@>9FNE^_QHQL?NW-2 M93G#45ZV)+G+]C]K,/O+J[%A)*-K%I%G75HA6+U7/-/URF].'"'NSB3M_C[M MO)?GT5V)^.MMT=J.W)C5U<(L*GOB+RWLMHA>1/F=<95W:T07C"Y!=;9=4O!" M>JZL+.E&_Q;/\^:+@*PST9;.#;]'HWQ:I@T9U$!_/=)GQ<<"C@N2![O$91KL^@;(PA5>DC.ZQ'':.A'5DF"YJ/&VI.,5$FAT M5^ /*"6J^.:LJ,JW2885E,ZIQPF!QPK: #>;=[?"0JD"P)'@63_I:WOB*^ M@YB,>9]S&4B212Q>B7Z!>.BAGF(!\%2F#24,57"A(F#2MFJ]25B7EE\D^-[F M=8'Q;?*6&>RN 2WM:J?UL^J>"XV>.+\:@#O&UO5/GI>SN\--( MG$<"$&QO1R->;6M'HYP+#]>,B:3$6823?Q',SM/Y&)VD-GN#DK,"A AAZ M1J835S<3TRGKT/.+.)WFR_R<,).8!AGMTFT+/>3!> Y@.7H73*.8! MF>;\_26/R2;0O@UT)UH)/INWFZ1+DMTAI[D2XU?Q0:L+?LRV^M/@O:=(96P( MC[R[%&@DX>%# BBNSP8@M_-(B%M:^T!4T$'B4&5K"X.<:AQ0%!2EX2 H,CN, MP>Y#HX8))X#U'($F4S VV$@]#33J+#.?*V\#JW/)FE$&9_9B ]>?GBZ(0O" MY[H1N26;_ /OZ(LE#BWJ/4>DS15!L//9!U#B2V+AR0TBZSP%NT^2\AOCTO M>,$^\_/!K:UHI[6S(IP#"\_37#P=F\^Y!]GV'[%9,0#\-. ]F6MBW'2ZP*(M MZE7Y @D\^I0&,]^J>C4)5LE=QT(\/_W$;NDCM)T$HD-$HL;6%@CY )LR). ' M$095:S *JM"N@W!-LQPG_XY7AFT*4T&(.#0YVQ)1X!$O"+JG8=<=S(56=-?1 MD(_[/K%K1K_&:=0J'$I)B'BHO&T!D15BS"AK#B(B@/Y@2 #QG<7DE$]E&$XF MZ9QL?B-/QGPH6*_!4)D"B=@"D40B#@T;!$!A-0& O.ZLI\LE3:&+)CTM3'$7I6(? MMUC8\@[%* 8^]#:7^(T/Q!L*SG:_?5> BHK @3&JKXF*47IG(3E?$G;/N_N5 MT=UA5/S#0>H\!H1B#60D!*."CS:%H0-B%%Y-1]&V9W%XR).R-4:^&Z% M'N8U"#5^@/L"@PI06,=5,56;526=>LM.^,)2Z34-MJL TE$KJZQ*M\4'\/"B ME3UJAEIYXS!3.1&_ !)_)6)7%TD5!L3D8-YS4.=89 !@H0DJBPOFL$5%)V#U'B=_8".LVWIQ5K,[5N\FQ,5/H+98^X,U7A, ,P>RP M0O>(@GA%8'% #8I'?653^ MH E?:&!6+&/-0X."]1H-E2D0B1VP>)H0>( !%83 *CKS/E_\MO/;RE]3*<$ M9S0E\TF6K2V#!%CC-0DP-&![XZ*&>C6[P M;)I=PE")"_K QR2NSF^=L@X\OV58?%YE^K2<447O+?4&QI/+36;*>[DXCPI M*%NU^E7]U(E7<+WDT.*ON/B/1-[_#U!+ P04 " "R@(M8NH1NGA\' #1 M40 % &UR:RTR,#(S,3(S,5]P&ULU9Q=;]LV%(;O!^P_:-ZU/R39 M:1(T+5PG*8RF:9!X7;=A(&B)MHE(I$%*B8-A_WVD9#>6HR.I[1*35W'D0^J\ M?,2O5Y)?OUW%D7-'A*2[@4-&I[/:_O_.7VCCW_N'?PM_// MU<=_VVV=0D39[11+XJB4F3QI;9UD-151AXMYU^OU_.XFL)5''J\D+43?^YM8 MM_OEX\5-L" Q;M.UCJ^E=#5EY=RCHZ-N]JT*E?189N4O>("3K!%K\W+ "/U? M>Q/6UH?:KM?VW%)&,B@MN,C/ZVNX[LZM,M!9&*:";L0M5>."]9 M)82%)-R<69>NKS@CR8-"39%N.RZ*$G1%4M64M9 D06?.[[HAH5VM2W_(!&;B MU#\HJWTXE8G 0;*I*<)3$F7UHR!F"J69Y90[TLJ,VAX8K*YKRV2Z'^_K!5 M,6E$<%=(.4C/5)"G/,:4U7#+@]# *$R[#0_3>DR_'([_LG!F6$ZS"E/9GF.\ MS F1*)&;(X^HU@?0*9DF>N4@JKH:'(SZ>QP9FW>Q&@'E]/JVT;O$,0&[75T1 MU-_38%G#I@G('17E. ?/CO/)8D\=0,->9]#K7?*$R-.4Z%7U1Q)/B2A!5!6. M^GL:)!NU>!%2K8YR0 =[ N1V#E\-MC(]J 8$A*/^@5V JG24 WJU)T!>\5+R M:WH0$([ZK^P"5*6C'-#AWGJ0OWTI^;4]J#0<]0_M E2EHQS0D:FK]:TEU 5E M9)R0^!OV7%^+H#V-@?_+AJN@ M@V]TP%.%$UU@#3(6A/8V"3)HQ3<2.V,)31ZNR9SJ M.WOY=A, 5A:*7+.V6C6\0 D KN=W,KX+UTB)%C@:LY"L/I"'2EX[L-LC_7GG-13:H0B3RKG!!( <#*."-D?:G%.(K>I5)IE=5#8B$2>5:9() "@)6A M%LA93,1#O!;]/%DU&PM(2R+/0$(&5 P-]46NTFE$@_.(8^BVV9,XY%GH MA^SF#U RU L9AJ%J:KG^HP6[E;1*XI%GH3L"Z0 >VC;.)BFH&*F/G\1$[3F; ML'N,1KZ%N[1R%0 W0SV2M0:]02&?Q)7@=S1_NZT6WDX1Y%NX3ZN0 F TU"!9 M"[GB,L'1GW0YXF$CB(4"R+=P,P * 0 :YY?2$3@?6KSC*@T%P173TW8(\NVZ=;:;.H#%.*OC0M4172TXJ[X9 MO1N&^E;=%"M-'T!DJ),Q9@$72RXRN=FJ=<13EHB'VO5>94G4MW#W5:\(8&NH M_S'!JW&HVH'.:/X;(0T># '*H+Z%>[$J+< KT(9Z(6.6$/US&/2.G.($KV\& MUG3/LB*H;]7\5RL%P&B<-;*1?D[5P!(G9T)P,>(JO:#F"?[Z@FA@U9S94! MUE"S9,3C6$\9/+B]6:A&DY_21/^JD]X#53^A4%$0#2R<0VL% 6"-,U$V#2 ? M5P4D?/=PK7,D+" 3LDK>J1/=UG3"=:#2PRNVL4@%P,\ZM*6K(WXYH3FXK'@VL,C^K=0#T?LB\Z>[^)E]V4">F M?S/PS7]02P$"% ,4 " "R@(M8;M-4A/@R E1 ( $ M@ $ 9#@P-SDU-60Q,&MA+FAT;5!+ 0(4 Q0 ( +* BUBQ@A+380, M ( ) 1 " 28S !D.# W.34U9&5X,S$S+FAT;5!+ 0(4 M Q0 ( +* BUC1U!*G9@, 'H) 1 " ;8V !D.# W M.34U9&5X,S$T+FAT;5!+ 0(4 Q0 ( +* BUCY7\IO@@4 X& 9 M " 4LZ !G.# W.34U9S T,3$Q.34P,C@Q,#%UP! "3 @ % M @ %F1 ;7)K+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4 " "R M@(M8^NO-'J4' #H30 % @ 'T10 ;7)K+3(P,C,Q,C,Q M7V1E9BYX;6Q02P$"% ,4 " "R@(M85R7\"G8) #F90 % M @ '+30 ;7)K+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4 " "R@(M8 MNH1NGA\' #140 % @ %S5P ;7)K+3(P,C,Q,C,Q7W!R ;92YX;6Q02P4& D "0!) @ Q%X end XML 21 d807955d10ka_htm.xml IDEA: XBRL DOCUMENT 0000310158 2023-01-01 2023-12-31 0000310158 2023-06-30 0000310158 2024-01-31 0000310158 mrk:A2.500NotesDue2034Member 2023-01-01 2023-12-31 0000310158 mrk:A1.375NotesDue2036Member 2023-01-01 2023-12-31 0000310158 mrk:A0.500NotesDue2024Member 2023-01-01 2023-12-31 0000310158 mrk:A1.875NotesDue2026Member 2023-01-01 2023-12-31 iso4217:USD shares true 0000310158 FY 10-K/A true 2023-12-31 --12-31 2023 false 1-6571 Merck & Co., Inc. 126 East Lincoln Avenue Rahway NJ 07065 908 740-4000 NJ 22-1918501 Common Stock ($0.50 par value) MRK NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 2532643872 292929000000 Proxy Statement for the Annual Meeting of Shareholders to be held May 28, 2024, to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report Merck & Co., Inc. (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Form 10-K”) with the Securities and Exchange Commission on February 26, 2024. The Company is filing this Amendment No. 1 (this “Amendment”) to the Original Form 10-K solely to correct the date of the Annual Meeting of Shareholders. In the Original Form 10-K, that date was inadvertently referenced as May 18, 2024. The date of the Annual Meeting of Shareholders is May 28, 2024. Accordingly, this Amendment is being filed solely to:     •   amend Part III, Items 10, 11, 12, 13 and 14 of the Original Form 10-K to correct the date of the Annual Meeting of Shareholders;     •   correct the date of the Annual Meeting of Shareholders on the cover of the filing; and     •   file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment under Item 15 of Part IV hereof pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. This Amendment does not reflect any events occurring after the filing of the Original Form 10-K or modify or update the disclosure contained therein in any way other than as required to reflect the correction discussed above. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K.